Compare Hershey Co (HSY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Travere Therapeutics Inc. Common Stock — how do they compare? Hershey Co trades at $165.63 (market cap $32.76B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Hershey Co is far larger — about 6.7× Travere Therapeutics Inc. Common Stock's market cap, and Hershey Co pays a 3.56% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HSY | TVTX | |
|---|---|---|
Market Cap | $32.76B | $4.88B |
Volume | 1,118,576 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $67.52 |
52-Week Low | $157.61 | $26.79 |
Typical Hold Time | 135 Days | 0 Days |
Enterprise Value | $37.89B | $5.01B |
Dividend Yield | 3.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSY trades at $164.25, up 0.25% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 38.38% gross margins and 32.81% ROE, though 2025 net income declined to $883M. Analyst consensus is mixed with 68.57% hold ratings but a $203.69 price target suggesting 24% upside. Recent news highlights dividend resumption and international leadership changes.
HSY presents a value opportunity with reasonable valuation multiples (P/E 22.27) and dividend yield, but faces headwinds from cocoa cost pressures and technical weakness. The stock's investment case hinges on margin recovery and successful execution of brand investments amid competitive consumer staples landscape.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
